Dr. Alan Russell (Ph.D., Imperial College) is the Vice President of Research (Large Molecule Discovery & Data Science) and Head, R&D Technology & Innovation at Amgen Inc. Alan leads a global team in the discovery and development of large molecule therapeutics and the use of data science across Research & Development. Alan is responsible for sustaining a robust, diverse talent pipeline and a culture of safety, teamwork, career development, inclusion and belonging. Previously, Alan was the Highmark Distinguished Career Professor in the Department of Chemical Engineering & the Director of the Disruptive Health Technology Institute at Carnegie Mellon University. From 2012-2016, in addition to his full-time role on the faculty of CMU, Alan served as the Executive Vice President and the Chief Innovation Officer of the Allegheny Health Network. Alan was also founder of Agentase LLC (acquired by FLIR/Teledyne), the CEO of BioHybrid Solutions, LLC, and Chairman of the Board of Directors of YouScript, Inc (acquired by Invitae) and Rheogene Inc (acquired by Invitrogen). He was the Founding Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, serving in that capacity from 2001-2011. Alan served on Science Board to the Food and Drug Administration for a decade and chaired the 10-year scientific review of the Center for Devices and Radiologic Health, publishing the key “Protecting the core of CDRH regulatory science in the face of financial and strategic threats” report. Alan’s research has impacted fields as diverse as chemical and polymer synthesis to tissue engineering and homeland defense, leading to a US Army “Greatest Invention” award and the founding of four companies. Alan has given more than 500 National and International invited lectures, published over 250 peer-reviewed articles that have been cited over 20,000 times, and holds dozens of US and International patents.

‍